Keywords: UK, NICE, Novartis, Xolair, Asthma

UK’s NICE rejects Novartis’ Xolair for children suffering severe persistent allergic asthma, on cost grounds

Article | 02 June 2010

Print This

The UK’s National Institute for Health and Clinical Excellence (NICE) has decided against recommending the use of Swiss drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in